HOME     CONTACT     BACK

 
 
 
THE PHARMA REVIEW (MAR 2010)

IPR Issues with Genetically Modified Organisms (GMOs)

Sujata Basu and Dr Rachana

Introduction
A scientific Discovery is like: falling in love or reaching the top of a mountain after a hard climb all in one or an ecstacy induced not by drugs but by the manifestation of a face of nature that no one has seen before. Today’s scientific and technological world is stressing on the importance of protecting our scientific discoveries with implementation of solid Intellectual Property Rights (IPR) in a tight maze of patents. Several resolved and unresolved IPR issues in this context come into the picture. Some of these issues include tug-of-war for patentship between the Celera Genomics Corp., a private company, and the US National Institutes of Health for the multibillion-dollar international effort of mapping the human genome; the Winterboers and the Asgrow Seed Company in Michigan in 1990 over the soybean seed varieties, and so on. This is definitely an indication that many bruising IPR battles lie ahead in the area of ‘biotechnology’. The solution lies in laying down definite, clear-cut, and open guidelines for the innovations.

 

For full text of this article contact the publisher on info@kppub.com

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email: info@kppub.com / fpc@vsnl.com, Website: http://www.kppub.com

 
 
 

 Copyright 2008. KONGPOSH PUBLICATIONS Pvt. Ltd.